Picture of Sinopharm logo

1099 — Sinopharm News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

Sinopharm unit gets approval for clinical trials of mRNA COVID vaccine

BEIJING, Jan 20 (Reuters) - Sinopharm's  1099.HK 
biotech unit has obtained regulatory approval for clinical
trials of its mRNA COVID-19 vaccine against the Omicron variant,
the company said on Friday.
    The unit, based in the commercial hub of Shanghai, has built
a research and development platform, as well as workshops with
annual production capacity of 2 billion doses of mRNA vaccine,
Sinopharm added. 
 (Reporting by Beijing newsroom; Editing by Clarence Fernandez)
 ((Ella.Cao@thomsonreuters.com;))

Recent news on Sinopharm

See all news